{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:03:36Z","timestamp":1790391816468,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","award":["Junior Clinician Scientist"],"award-info":[{"award-number":["Junior Clinician Scientist"]}],"id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","award":["Clinician Scientist"],"award-info":[{"award-number":["Clinician Scientist"]}],"id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FI 965\/5-1"],"award-info":[{"award-number":["FI 965\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KFO-192"],"award-info":[{"award-number":["KFO-192"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung","doi-asserted-by":"publisher","award":["81Z5400153"],"award-info":[{"award-number":["81Z5400153"]}],"id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The objective was to investigate the role of gene expression and plasma levels of the muscular protein myostatin in intensive care unit-acquired weakness (ICUAW). This was performed to evaluate a potential clinical and\/or pathophysiological rationale of therapeutic myostatin inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis from pooled data of two prospective studies to assess the dynamics of myostatin plasma concentrations (day 4, 8 and 14) and myostatin gene (\n                      <jats:italic>MSTN<\/jats:italic>\n                      ) expression levels in skeletal muscle (day 15) was performed. Associations of myostatin to clinical and electrophysiological outcomes, muscular metabolism and muscular atrophy pathways were investigated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>MSTN<\/jats:italic>\n                      gene expression (median [IQR] fold change: 1.00\u00a0[0.68\u20131.54] vs. 0.26\u00a0[0.11\u20130.80];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) and myostatin plasma concentrations were significantly reduced in all critically ill patients when compared to healthy controls. In critically ill patients, myostatin plasma concentrations increased over time (median [IQR] fold change: day 4: 0.13 [0.08\/0.21] vs. day 8: 0.23 [0.10\/0.43] vs. day 14: 0.40 [0.26\/0.61];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Patients with ICUAW versus without ICUAW showed significantly lower\n                      <jats:italic>MSTN<\/jats:italic>\n                      gene expression levels (median [IQR] fold change: 0.17 [0.10\/0.33] and 0.51 [0.20\/0.86];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047). Myostatin levels were directly correlated with muscle strength (correlation coefficient 0.339;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.020) and insulin sensitivity index (correlation coefficient 0.357;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.015). No association was observed between myostatin plasma concentrations as well as\n                      <jats:italic>MSTN<\/jats:italic>\n                      expression levels and levels of mobilization, electrophysiological variables, or markers of atrophy pathways.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Muscular gene expression and systemic protein levels of myostatin are downregulated during critical illness. The previously proposed therapeutic inhibition of myostatin does therefore not seem to have a pathophysiological rationale to improve muscle quality in critically ill patients.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      :\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/ISRCTN77569430\">ISRCTN77569430<\/jats:ext-link>\n                      \u201413th of February 2008 and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/ISRCTN19392591\">ISRCTN19392591<\/jats:ext-link>\n                      17th of February 2011.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-022-04101-1","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T05:03:48Z","timestamp":1659503028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Muscular myostatin gene expression and plasma concentrations are decreased in critically ill patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Julius J.","family":"Grunow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Reiher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas M.","family":"Carbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian Jo","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg C.","family":"Schefold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Z\u2019Graggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan J.","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Fielitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Spranger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-0172","authenticated-orcid":false,"given":"Steffen","family":"Weber-Carstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Wollersheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"issue":"12","key":"4101_CR1","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1164\/rccm.201411-2011ST","volume":"190","author":"E Fan","year":"2014","unstructured":"Fan E, Cheek F, Chlan L, Gosselink R, Hart N, Herridge MS, Hopkins RO, Hough CL, Kress JP, Latronico N, et al. An official American Thoracic Society Clinical Practice guideline: the diagnosis of intensive care unit-acquired weakness in adults. Am J Respir Crit Care Med. 2014;190(12):1437\u201346.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"4101_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/1751143714563016","volume":"16","author":"RT Appleton","year":"2015","unstructured":"Appleton RT, Kinsella J, Quasim T. The incidence of intensive care unit-acquired weakness syndromes: a systematic review. J Intensive Care Soc. 2015;16(2):126\u201336.","journal-title":"J Intensive Care Soc"},{"issue":"6","key":"4101_CR3","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/jcsm.12620","volume":"11","author":"JC Schefold","year":"2020","unstructured":"Schefold JC, Wollersheim T, Grunow JJ, Luedi MM, Z\u2019Graggen WJ, Weber-Carstens S. Muscular weakness and muscle wasting in the critically ill. J Cachexia Sarcopenia Muscle. 2020;11(6):1399\u2013412.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"4101_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1164\/rccm.201312-2257OC","volume":"190","author":"G Hermans","year":"2014","unstructured":"Hermans G, Van Mechelen H, Clerckx B, Vanhullebusch T, Mesotten D, Wilmer A, Casaer MP, Meersseman P, Debaveye Y, Van Cromphaut S, et al. Acute outcomes and 1-year mortality of intensive care unit-acquired weakness. A cohort study and propensity-matched analysis. Am J Respir Crit Care Med. 2014;190(4):410\u201320.","journal-title":"Am J Respir Crit Care Med"},{"key":"4101_CR5","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s00134-020-05927-5","volume":"46","author":"N Van Aerde","year":"2020","unstructured":"Van Aerde N, Meersseman P, Debaveye Y, Wilmer A, Gunst J, Casaer MP, Bruyninckx F, Wouters PJ, Gosselink R, Van den Berghe G, et al. Five-year impact of ICU-acquired neuromuscular complications: a prospective, observational study. Intensive Care Med. 2020;46:1184\u201393.","journal-title":"Intensive Care Med"},{"issue":"4","key":"4101_CR6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s00134-014-3224-9","volume":"40","author":"T Wollersheim","year":"2014","unstructured":"Wollersheim T, Woehlecke J, Krebs M, Hamati J, Lodka D, Luther-Schroeder A, Langhans C, Haas K, Radtke T, Kleber C, et al. Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness. Intensive Care Med. 2014;40(4):528\u201338.","journal-title":"Intensive Care Med"},{"issue":"6","key":"4101_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1046\/j.1365-2990.1998.00144.x","volume":"24","author":"TR Helliwell","year":"1998","unstructured":"Helliwell TR, Wilkinson A, Griffiths RD, McClelland P, Palmer TE, Bone JM. Muscle fibre atrophy in critically ill patients is associated with the loss of myosin filaments and the presence of lysosomal enzymes and ubiquitin. Neuropathol Appl Neurobiol. 1998;24(6):507\u201317.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"15","key":"4101_CR8","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.2013.278481","volume":"310","author":"ZA Puthucheary","year":"2013","unstructured":"Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, Hopkinson NS, Phadke R, Dew T, Sidhu PS, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310(15):1591\u2013600.","journal-title":"JAMA"},{"issue":"7","key":"4101_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1164\/rccm.201512-2344OC","volume":"194","author":"C Dos Santos","year":"2016","unstructured":"Dos Santos C, Hussain SN, Mathur S, Picard M, Herridge M, Correa J, Bain A, Guo Y, Advani A, Advani SL, et al. Mechanisms of chronic muscle wasting and dysfunction after an intensive care unit stay. A pilot study. Am J Respir Crit Care Med. 2016;194(7):821\u201330.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"4101_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1042\/CS20110233","volume":"122","author":"M Klaude","year":"2012","unstructured":"Klaude M, Mori M, Tjader I, Gustafsson T, Wernerman J, Rooyackers O. Protein metabolism and gene expression in skeletal muscle of critically ill patients with sepsis. Clin Sci (Lond). 2012;122(3):133\u201342.","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"4101_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1164\/rccm.201209-1649OC","volume":"187","author":"S Weber-Carstens","year":"2013","unstructured":"Weber-Carstens S, Schneider J, Wollersheim T, Assmann A, Bierbrauer J, Marg A, Al Hasani H, Chadt A, Wenzel K, Koch S, et al. Critical illness myopathy and GLUT4: significance of insulin and muscle contraction. Am J Respir Crit Care Med. 2013;187(4):387\u201396.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"4101_CR12","doi-asserted-by":"publisher","first-page":"R5","DOI":"10.1186\/cc7694","volume":"13","author":"G Hermans","year":"2009","unstructured":"Hermans G, Schrooten M, Van Damme P, Berends N, Bouckaert B, De Vooght W, Robberecht W, Van den Berghe G. Benefits of intensive insulin therapy on neuromuscular complications in routine daily critical care practice: a retrospective study. Crit Care. 2009;13(1):R5.","journal-title":"Crit Care"},{"issue":"19","key":"4101_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa011300","volume":"345","author":"G van den Berghe","year":"2001","unstructured":"van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359\u201367.","journal-title":"N Engl J Med"},{"issue":"6628","key":"4101_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83\u201390.","journal-title":"Nature"},{"issue":"26","key":"4101_CR15","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa040933","volume":"350","author":"M Schuelke","year":"2004","unstructured":"Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350(26):2682\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"4101_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/ng0997-71","volume":"17","author":"L Grobet","year":"1997","unstructured":"Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Menissier F, Massabanda J, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet. 1997;17(1):71\u20134.","journal-title":"Nat Genet"},{"issue":"23","key":"4101_CR17","doi-asserted-by":"publisher","first-page":"12457","DOI":"10.1073\/pnas.94.23.12457","volume":"94","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA. 1997;94(23):12457\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1\u20132","key":"4101_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.mce.2010.09.008","volume":"332","author":"M Hayot","year":"2011","unstructured":"Hayot M, Rodriguez J, Vernus B, Carnac G, Jean E, Allen D, Goret L, Obert P, Candau R, Bonnieu A. Myostatin up-regulation is associated with the skeletal muscle response to hypoxic stimuli. Mol Cell Endocrinol. 2011;332(1\u20132):38\u201347.","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"4101_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/eurjhf\/hfq039","volume":"12","author":"I George","year":"2010","unstructured":"George I, Bish LT, Kamalakkannan G, Petrilli CM, Oz MC, Naka Y, Sweeney HL, Maybaum S. Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail. 2010;12(5):444\u201353.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"4101_CR20","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3390\/ijms21031167","volume":"21","author":"J Aravena","year":"2020","unstructured":"Aravena J, Abrigo J, Gonzalez F, Aguirre F, Gonzalez A, Simon F, Cabello-Verrugio C. Angiotensin (1\u20137) decreases myostatin-induced NF-kappaB signaling and skeletal muscle atrophy. Int J Mol Sci. 2020;21(3):1167.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4101_CR21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1055\/a-0641-5546","volume":"127","author":"M Amor","year":"2019","unstructured":"Amor M, Itariu BK, Moreno-Viedma V, Keindl M, Jurets A, Prager G, Langer F, Grablowitz V, Zeyda M, Stulnig TM. Serum myostatin is upregulated in obesity and correlates with insulin resistance in humans. Exp Clin Endocrinol Diabetes. 2019;127(8):550\u20136.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"11","key":"4101_CR22","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1249\/MSS.0b013e3181e0b9a8","volume":"42","author":"DS Hittel","year":"2010","unstructured":"Hittel DS, Axelson M, Sarna N, Shearer J, Huffman KM, Kraus WE. Myostatin decreases with aerobic exercise and associates with insulin resistance. Med Sci Sports Exerc. 2010;42(11):2023\u20139.","journal-title":"Med Sci Sports Exerc"},{"key":"4101_CR23","doi-asserted-by":"publisher","first-page":"32495","DOI":"10.1038\/srep32495","volume":"6","author":"SK Coleman","year":"2016","unstructured":"Coleman SK, Rebalka IA, D\u2019Souza DM, Deodhare N, Desjardins EM, Hawke TJ. Myostatin inhibition therapy for insulin-deficient type 1 diabetes. Sci Rep. 2016;6:32495.","journal-title":"Sci Rep"},{"issue":"3","key":"4101_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/ijo.2015.200","volume":"40","author":"J Dong","year":"2016","unstructured":"Dong J, Dong Y, Dong Y, Chen F, Mitch WE, Zhang L. Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues. Int J Obes (Lond). 2016;40(3):434\u201342.","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"4101_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1600-0838.2009.01044.x","volume":"21","author":"JG Jespersen","year":"2011","unstructured":"Jespersen JG, Nedergaard A, Andersen LL, Schjerling P, Andersen JL. Myostatin expression during human muscle hypertrophy and subsequent atrophy: increased myostatin with detraining. Scand J Med Sci Sports. 2011;21(2):215\u201323.","journal-title":"Scand J Med Sci Sports"},{"key":"4101_CR26","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/jcsm.12428","volume":"10","author":"T Wollersheim","year":"2019","unstructured":"Wollersheim T, Grunow JJ, Carbon NM, Haas K, Malleike J, Ramme SF, Schneider J, Spies CD, Mardian S, Mai K, et al. Muscle wasting and function after muscle activation and early protocol-based physiotherapy: an explorative trial. J Cachexia Sarcopenia Muscle. 2019;10:734\u201347.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"Suppl 1","key":"4101_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00101-015-0071-1","volume":"64","author":"T Bein","year":"2015","unstructured":"Bein T, Bischoff M, Bruckner U, Gebhardt K, Henzler D, Hermes C, Lewandowski K, Max M, Nothacker M, Staudinger T, et al. S2e guideline: positioning and early mobilisation in prophylaxis or therapy of pulmonary disorders\u202f: revision 2015: S2e guideline of the German Society of Anaesthesiology and Intensive Care Medicine (DGAI). Anaesthesist. 2015;64(Suppl 1):1\u201326.","journal-title":"Anaesthesist"},{"issue":"10052","key":"4101_CR28","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(16)31637-3","volume":"388","author":"SJ Schaller","year":"2016","unstructured":"Schaller SJ, Anstey M, Blobner M, Edrich T, Grabitz SD, Gradwohl-Matis I, Heim M, Houle T, Kurth T, Latronico N, et al. Early, goal-directed mobilisation in the surgical intensive care unit: a randomised controlled trial. Lancet. 2016;388(10052):1377\u201388.","journal-title":"Lancet"},{"issue":"22","key":"4101_CR29","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1001\/jama.288.22.2859","volume":"288","author":"B De Jonghe","year":"2002","unstructured":"De Jonghe B, Sharshar T, Lefaucheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, Cerf C, Renaud E, Mesrati F, Carlet J, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA. 2002;288(22):2859\u201367.","journal-title":"JAMA"},{"issue":"3","key":"4101_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/jnnp.2009.192997","volume":"82","author":"S Koch","year":"2011","unstructured":"Koch S, Spuler S, Deja M, Bierbrauer J, Dimroth A, Behse F, Spies CD, Wernecke KD, Weber-Carstens S. Critical illness myopathy is frequent: accompanying neuropathy protracts ICU discharge. J Neurol Neurosurg Psychiatry. 2011;82(3):287\u201393.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"4101_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nrd4467","volume":"14","author":"S Cohen","year":"2015","unstructured":"Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov. 2015;14(1):58\u201374.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"4101_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531\u201343.","journal-title":"Cell"},{"issue":"4","key":"4101_CR33","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1152\/japplphysiol.01183.2010","volume":"110","author":"KT Murphy","year":"2011","unstructured":"Murphy KT, Cobani V, Ryall JG, Ibebunjo C, Lynch GS. Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice. J Appl Physiol (1985). 2011;110(4):1065\u201372.","journal-title":"J Appl Physiol (1985)"},{"issue":"4","key":"4101_CR34","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/mus.25268","volume":"55","author":"C Campbell","year":"2017","unstructured":"Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55(4):458\u201364.","journal-title":"Muscle Nerve"},{"issue":"1","key":"4101_CR35","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41467-017-01486-4","volume":"8","author":"V Mariot","year":"2017","unstructured":"Mariot V, Joubert R, Hourde C, Feasson L, Hanna M, Muntoni F, Maisonobe T, Servais L, Bogni C, Le Panse R, et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017;8(1):1859.","journal-title":"Nat Commun"},{"key":"4101_CR36","doi-asserted-by":"publisher","first-page":"15153","DOI":"10.1038\/ncomms15153","volume":"8","author":"E Latres","year":"2017","unstructured":"Latres E, Mastaitis J, Fury W, Miloscio L, Trejos J, Pangilinan J, Okamoto H, Cavino K, Na E, Papatheodorou A, et al. Activin A more prominently regulates muscle mass in primates than does GDF8. Nat Commun. 2017;8:15153.","journal-title":"Nat Commun"},{"issue":"4","key":"4101_CR37","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/jcb.22796","volume":"111","author":"IJ Smith","year":"2010","unstructured":"Smith IJ, Aversa Z, Alamdari N, Petkova V, Hasselgren PO. Sepsis downregulates myostatin mRNA levels without altering myostatin protein levels in skeletal muscle. J Cell Biochem. 2010;111(4):1059\u201373.","journal-title":"J Cell Biochem"},{"issue":"3","key":"4101_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00415-016-8379-6","volume":"264","author":"PM Burch","year":"2017","unstructured":"Burch PM, Pogoryelova O, Palandra J, Goldstein R, Bennett D, Fitz L, Guglieri M, Bettolo CM, Straub V, Evangelista T, et al. Reduced serum myostatin concentrations associated with genetic muscle disease progression. J Neurol. 2017;264(3):541\u201353.","journal-title":"J Neurol"},{"issue":"8","key":"4101_CR39","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/diagnostics10080574","volume":"10","author":"TH Wirtz","year":"2020","unstructured":"Wirtz TH, Loosen SH, Buendgens L, Kurt B, Abu Jhaisha S, Hohlstein P, Brozat JF, Weiskirchen R, Luedde T, Tacke F, et al. Low myostatin serum levels are associated with poor outcome in critically ill patients. Diagnostics (Basel). 2020;10(8):574.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"4101_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1210\/en.2011-1687","volume":"153","author":"S Kalista","year":"2012","unstructured":"Kalista S, Schakman O, Gilson H, Lause P, Demeulder B, Bertrand L, Pende M, Thissen JP. The type 1 insulin-like growth factor receptor (IGF-IR) pathway is mandatory for the follistatin-induced skeletal muscle hypertrophy. Endocrinology. 2012;153(1):241\u201353.","journal-title":"Endocrinology"},{"issue":"17","key":"4101_CR41","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13837","volume":"6","author":"XH Liu","year":"2018","unstructured":"Liu XH, Bauman WA, Cardozo CP. Myostatin inhibits glucose uptake via suppression of insulin-dependent and -independent signaling pathways in myoblasts. Physiol Rep. 2018;6(17): e13837.","journal-title":"Physiol Rep"},{"issue":"3","key":"4101_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/thoraxjnl-2014-206225","volume":"70","author":"SA Bloch","year":"2015","unstructured":"Bloch SA, Lee JY, Syburra T, Rosendahl U, Griffiths MJ, Kemp PR, Polkey MI. Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs. Thorax. 2015;70(3):219\u201328.","journal-title":"Thorax"},{"issue":"4","key":"4101_CR43","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/jcsm.12096","volume":"7","author":"MS Patel","year":"2016","unstructured":"Patel MS, Lee J, Baz M, Wells CE, Bloch S, Lewis A, Donaldson AV, Garfield BE, Hopkinson NS, Natanek A, et al. Growth differentiation factor-15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo. J Cachexia Sarcopenia Muscle. 2016;7(4):436\u201348.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"11","key":"4101_CR44","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00424-018-2180-6","volume":"470","author":"SJ Schaller","year":"2018","unstructured":"Schaller SJ, Nagashima M, Schonfelder M, Sasakawa T, Schulz F, Khan MAS, Kem WR, Schneider G, Schlegel J, Lewald H, et al. GTS-21 attenuates loss of body mass, muscle mass, and function in rats having systemic inflammation with and without disuse atrophy. Pflugers Arch. 2018;470(11):1647\u201357.","journal-title":"Pflugers Arch"},{"issue":"5","key":"4101_CR45","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1152\/japplphysiol.00679.2007","volume":"103","author":"E Louis","year":"2007","unstructured":"Louis E, Raue U, Yang Y, Jemiolo B, Trappe S. Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle. J Appl Physiol (1985). 2007;103(5):1744\u201351.","journal-title":"J Appl Physiol (1985)"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-022-04101-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T06:05:06Z","timestamp":1659506706000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-022-04101-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4101"],"URL":"https:\/\/doi.org\/10.1186\/s13054-022-04101-1","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"14 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for both studies had been granted by the institutional review board (EA2\/061\/06 and EA2\/041\/10) and conformed to the Declaration of Helsinki. Patients were included after written informed consent by a legal proxy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SJ Schaller reports grants and non-financial support from ESICM (Brussels, Belgium), Fresenius (Germany), Liberate Medical LLC (Crestwood, USA), STIMIT AG (Nidau, Switzerland), MSD (Haar, Germany) as well as from Technical University of Munich, Germany, from national (e.g., DGAI) and international (e.g., ESICM) medical societies (or their congress organizers) in the field of anesthesiology and intensive care, all outside the submitted work; SJS holds stocks in small amounts from Alphabet Inc., Bayer AG, Rh\u00f6n-Klinikum AG, and Siemens AG. These did not have any influence on this study. JCS reports (full departmental disclosure) grants from Orion Pharma, Abbott Nutrition International, B. Braun Medical AG, CSEM AG, Edwards Lifesciences Services GmbH, Kenta Biotech Ltd., Maquet Critical Care AB, Omnicare Clinical Research AG, Nestle, Pierre Fabre Pharma AG, Pfizer, Bard Medica S.A., Abbott AG, Anandic Medical Systems, Pan Gas AG Healthcare, Bracco, Hamilton Medical AG, Fresenius Kabi, Getinge Group Maquet AG, Dr\u00e4ger AG, Teleflex Medical GmbH, Glaxo Smith Kline, Merck Sharp and Dohme AG, Eli Lilly and Company, Baxter, Astellas, Astra Zeneca, CSL Behring, Novartis, Covidien, Nycomed, and Phagenesis, outside of the submitted work. The money went into departmental funds, no personal financial gain applies. SWC reports scientific grants from Dr\u00e4gerwerk AG & Co. KGaA, outside of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}